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Abstract : This report presents a case of a 74-year-old man who showed dramatic therapeutic response to treat-
ment of coronavirus infectious disease-19 (COVID-19) pneumonia. He reported four-day history of sustained fe-
ver and acute progressive dyspnea. He developed severe respiratory failure, underwent urgent endotracheal 
intubation and showed marked elevation of inflammatory and coagulation markers such as c-reactive protein 
(CRP), ferritin, lactate dehydrogenase (LDH) and D-dimer. Chest computed tomography (CT) demonstrated dif-
fuse consolidation and ground glass opacity (GGO). We diagnosed critical COVID-19 pneumonia with detailed 
sick contact history and naso-pharyngeal swab of a reverse-transcriptase-polymerase-chain reaction (RT-PCR) 
assay testing. He received anti-viral drug, anti-interleukin (IL-6) receptor antagonist and intravenous methyl-
prednisolone. After commencing combined intensive therapy, he showed dramatic improvement of clinical con-
dition, serum biomarkers and radiological findings. Early diagnosis and rapid critical care management may 
provide meaningful clinical benefit even if severe case. J. Med. Invest. 68 : 192-195, February, 2021
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INTRODUCTION
 
Coronavirus infectious disease-19 (COVID-19), caused by 
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 
has spread and over four million people have been infected 
throughout the world. SARS-CoV-2 infection has several risk 
factors for disease progression, including age, male sex, underly-
ing comorbid disease, and obesity (1). Although optimal therapy 
has not been defined conclusively, anti-viral drugs and anti-in-
flammatory agents are the cornerstones of treatment (2). Elderly 
men with severe COVID-19 pneumonia often have a very poor 
prognosis. In 40% of symptomatic patients, they usually report 
dyspnea 7 days after development of initial symptoms (3). 5% of 
the COVID-19 patients presents critical illness. We herein report 
a case of a critically ill elderly man with COVID-19 pneumonia 
who was a super-responder to combination therapy. Written in-
formed consent was obtained from the patient. 
CASE REPORT
A 74-year-old Japanese man presented to our hospital with se-
vere dyspnea and a sustained low-grade fever. He had a sick con-
tact through meeting with a known index case of COVID-19 ten 
days prior to admission. His past medical history was hyperten-
sion. He had a 54-pack-year history of tobacco exposure and was 
a current smoker with heavy alcohol consumption. His initial 
vital signs were : blood pressure, 154 / 82 mmHg ; heart rate, 158 
beats / minute ; respiratory rate, 20 breaths / minute ; body tem-
perature, 38.8℃. His SpO2 was only 46% on a reservoir oxygen 
mask at 15 liters per minute, but his consciousness was clear. 
Body mass index was 22.6 kg / m2. Physical examination showed 
severe acute distress. There was no lymphadenopathy. Chest 
auscultation revealed no adventitious sounds. Cardiovascular 
examination showed no murmurs, rubs and gallops. There were 
no rashes, petechiae, muscle pain and joint pain on the extrem-
ities. Chest radiography revealed bilateral peripheral dominant 
infiltration. Initial chest computed tomography (CT) showed 
diffuse extensive consolidation and ground glass opacity (GGO) 
with vascular enhancement. Over 80% of total lung parenchy-
ma had interstitial features(Figure 1A and 1B). Laboratory 
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Figure 1.　Chest CT during acute phase of illness
(a) Bilateral extensive GGO and consolidation at the subcarinal level.
(b) Inter-lobar fissure level, there were more dense consolidation in 
dorsal area. In addition, there was vascular enhancement sign (arrow).
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tests showed : white blood cell count, 15900 / mm3 ; lymphocytes 
1065 / mm3 ; c-reactive protein (CRP) 32 mg / dL ; lactate dehy-
drogenase (LDH), 801 U / L ; Ferritin 2767 ng / mL ; D-dimer 
2.1 μg / mL. A reverse-transcriptase-polymerase-chain reaction 
(RT-PCR) assay detected the presence of SARS-CoV-2 RNA in 
nasopharyngeal swab (Table 1). Based on the result of PCR and 
medical interview, chest CT findings and laboratory examina-
tion, we diagnosed this case as critical COVID-19 pneumonia.
The patient underwent urgent endotracheal intubation and 
was admitted to the intensive care unit (ICU) for comprehensive 
management. Initial ratio of arterial oxygen partial pressure to 
fractional inspired oxygen (P / F ratio) was 115 in fractional in-
spired oxygen (FiO2 )100% with positive end-expiratory pressure 
was 14 cm H2O in the setting of pressure 20 cm H2O and tidal 
volume was 360 ml with volume-controlled assist ventilation 
mode. 
Due to the severity of disease in this patients, intensive ther-
apy was initiated immediately, consisting of oral favipiravir 
3600 mg / day, intravenous tocilizumab 480 mg (8 mg / kg / day) 
and intravenous methylprednisolone (MP) 60 mg / kg / day 
(1 mg / kg / day). Informed consent for treatment was obtained 
from the patient‘s family. Intravenous MP continued for five 
days and favipiravir continued at a maintenance dose with 
1600 mg / day until he developed new erythema over his trunk 
and arms a few days after starting the regimen. Favipravir 
was stopped on day 5 due to concern for possible adverse drug 
reaction, although the possibility of cutaneous manifestation of 
COVID-19 was possible. His clinical condition and oxygenation 
had improved significantly with intensive anti-inflammatory 
drugs and lung protective ventilation. On day 12, he was success-
fully extubated without complications such as respiratory muscle 
exhaustion or secretion difficulty. The clinical course is outlined 
in Figure 2, showing that serum CRP, ferritin, and D-dimer 
revealed marked decrease over the first week. In addition, the 
peripheral lymphocyte count increased to normal level accom-
panied by clinical improvement. A repeat chest CT performed on 
the day of extubation demonstrated dramatic improvement of his 
diffuse infiltrates (Figure 3A and 3B). After transfer to medical 
ward, he recovered uneventfully without supplemental oxygen 
and underwent rehabilitation. He was discharged home after 
two consecutive nasopharyngeal swabs were negative by PCR.
 
DISCUSSION
SARS-CoV-2 was identified in China during December 2019. 
This virus causes disease of variable severity, ranging from 
asymptomatic cases to critical illness requiring mechanical 
ventilation and vasopressor support, complicated by multi organ 
failure (4). Approximately 80% of infected patients present with 
mild disease, 15% cases have more severe presentations, and 
5% are critically ill (5). Several risk factors have been reported 
for development of COVID 19 such as age, male, obesity, smok-
ing, hypertension, diabetes mellitus, chronic kidney disease, 
cardiovascular disease, chronic lung disease, malignancy and 
immunosuppression (6). Furthermore, the risk factors for over-
whelming of COVID-19 progression have also been clarified, 
including elevated CRP, ferritin, and D-dimer, and decreased 
lymphocyte counts (7). Our case had four risk factors including 
age, male sex, tobacco exposure, and hypertension. Regarding 
hypertension, our case received amlodipine besilate. During ad-
mission, his blood pressure was relatively well controlled without 
anti-hypertension drug. In patients with COVID-19, there is a 
Table 1.　Laboratory findings on admission
Hematology Chemistry
White blood cell 15900 / μL Blood urea nitrogen 26 mg / dL
  Neutrophil 89.1% Creatinine 0.94 mg / dL
  Lymphocyte 6.7% Sodium 139 mmol / L
  Eosinophil 0% Potassium  4.1 mmol / L
Red blood cell 4.33×106 / μL LDH 801 U / L
Hemoglobin 14.3 g / dL AST 170 U / L
Hematocrit 42.3% ALT 144 U / L
  Platelet 196000 / μL C-reactive protein 32 mg / dL
Ferritin 2767 ng / mL
Coagulation Infection panel
  D-dimer 2.1 μg / mL   Nasopharyngeal COVID-19
  RT-PCR (+)
Definition of abbreviations : LDH = lactate dehydrogenase ; 
AST = aspartate aminotransferase ; ALT = alanine aminotransfer-
ase ; COVID-19 = Coronavirus infectious disease-19 ; RT-PCR = Re-
verse-transcriptase-polymerase-chain reaction.
Figure 2.　Clinical course
Definitions of abbreviations : MP = methylprednisolone ; CRP = c-reactive 
protein ; P / F ratio = ratio of arterial oxygen partial pressure to 
fractional inspired oxygen ; FiO2 ; = fractional inspired oxygen.
Figure 3.　Chest CT during the recovery phase
(a) Marked improvement in the extensive infiltrates at the subcarinal 
level.
(b) At the inter-lobar fissure level, dense consolidation was dramatically 
improved with organization (arrow).
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report that ACE2 is down-regulated after the SARS-CoV-2 is 
infected through ACE2, resulting in continuous hypertension by 
persistent activation of Renin-Angiotensin-Aldosterone System 
(8). Hypertension is risk factor. However, any medication class 
had no association with severe illness of COVID-19. Therefore, 
adequate management of blood pressure is important. In addi-
tion, his laboratory risk factors for disease progression included 
elevated CRP, ferritin, and D-dimer. Furthermore, his initial 
chest CT demonstrated diffuse extensive consolidation and GGO 
which resembled severe acute respiratory distress syndrome 
(ARDS). Therefore, he showed very severe COVID-19 pneu-
monia initially with potential for a poor outcome. However, his 
actual outcome was favorable after a dramatic clinical response 
to intensive therapy with favipiravir, tocilizumab, and MP. At 
April 2020, remdesivir was not available in Japan. Therefore, 
we used favipiravir, methylprednisolone and tocilizumab for our 
case. We feel that early intervention with this regimen may pro-
vide effective rescue therapy for similar cases of critical COVID-
19 pneumonia. 
From clinical and imaging response of our case, what ap-
peared to be extensive consolidation and GGO might have 
been reversible organizing diffuse alveolar damage (DAD) with 
vascular invasion. In addition, bronchial dilatation was not sig-
nificant on the initial chest CT. Therefore, this patient’s clinical 
stage coincided with the organizing phase rather than the fibrot-
ic phase of ARDS (9, 10).
Anti-viral and anti-inflammatory medications are the two 
core pillars of the management of severe COVID-19 pneumo-
nia. Favipiravir is an anti-viral agent that blocks replication of 
RNA-viruses. Several reports have shown clinical effectiveness 
of favipiravir for COVID-19 pneumonia (11). Favipiravir may 
be used with careful monitoring of liver function and uric acid. 
Pregnancy is a contraindication for favipiravir due to the possi-
bility of fetal anomalies. We hypothesize that early introduction 
of favipiravir can promote more effective suppression of virus 
replication.
Tocilizumab is an interleukin-6 (IL-6) receptor antagonist 
which is usually used for IL-6 mediated diseases such as rheu-
matoid arthritis, and multi-centric Castleman disease. For criti-
cal COVID-19 pneumonia, IL-6 associated cytokine storm often 
plays a major role in disease progression, so tocilizumab likely 
contributes by reducing the chance of virus associated cytokine 
storm in COVID-19 severe pneumonia (12, 13). Recently, two 
retrospective cohort study about effectiveness of tocilizumab for 
severe COVID-19 pneumonia were reported. Guaraldi et al., re-
ported that tocilizumab treatment was associated with a reduced 
risk of invasive mechanical ventilation or death (adjusted hazard 
ratio 0.61, 95% confidence interval [CI] 0.40-0.92 ; p = 0.020). 24 
(13%) of 179 patients treated with tocilizumab were diagnosed 
with new infections, versus 14 (4%) of 365 patients treated 
with standard of care alone (p < 0.0001) (14). Kewan et al. also 
reported that the median time to clinical improvement in to-
cilizumab vs. no tocilizumab cohorts was 8 days (Interquartile 
range [IQR] : 6.25-9.75 days) vs. 13 days (IQR : 9.75-15.25 days) 
among patients who required mechanical ventilation at any 
time (Hazard ratio for clinical improvement : 1.83, 95% CI : 0.57-
5.84). The median duration of vasopressor support and invasive 
mechanical ventilation were 2 days (IQR : 1.75-4.25 days) vs. 
5 days (IQR : 4-8 days), p = 0.039, and 7 days (IQR : 4-14 days) 
vs. 10 days (IQR : 5-15 days) in tocilizumab vs. no tocilizumab 
cohorts, p = 0.11, respectively (15). Our case showed marked 
elevation of CRP, LDH and ferritin and very severe ARDS sta-
tus. Based on these clinical information, we considered our case 
as virus associated cytokine storm state. When tocilizumab is 
used, monitoring for the development of bacterial infection and 
decreased CRP is essential. 
The use of intravenous corticosteroids is controversial for 
viral pneumonia. Intravenous corticosteroids showed no clinical 
benefit for SARS or Middle East respiratory syndrome, because 
of delayed viral clearance and secondary infection due to cortico-
steroid (16). There are no controlled clinical trials of corticoste-
roids in COVID-19 pneumonia. However, several reports have 
shown that low dose, short-term methylprednisolone was associ-
ated with shorter durations of supplemental oxygen or reduction 
of need for mechanical ventilation in COVID-19 and communi-
ty-acquired pneumonia with septic shock (17, 18). Based on these 
data, Infectious Disease Society of America guideline panel 
recommends the use of corticosteroids in the context of a clinical 
trial for ARDS due to COVID-19. Our experience suggests that 
low dose, short-term use of methylprednisolone might be benefi-
cial in cases of COVID-19 pneumonia with severe ARDS.
In conclusion, we observed a super-responder to intensive 
therapy for critical COVID-19 pneumonia. Early introduction 
of intensive combination therapy requires suppression of both 
viral replication and inflammation, especially control of cytokine 
storm, in order to secure good outcomes in patients with critical 
COVID-19 pneumonia.
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